SELLAS生命科学集团宣布首名患者入组SLS009一线治疗初诊急性髓系白血病试验

美股速递
Mar 12

SELLAS生命科学集团(SELLAS Life Sciences Group Inc.)宣布,其创新药物SLS009在一线治疗初诊急性髓系白血病(AML)的临床试验中,已完成首名患者入组。这一进展标志着该疗法正式进入临床验证阶段,为AML患者带来新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10